{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:09Z","timestamp":1794072969079,"version":"4.8.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rpth.2024.102640","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:17:47Z","timestamp":1732810667000},"page":"102640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Gene therapy in hemophilia: the dawn of a new era"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-0552","authenticated-orcid":false,"given":"Andrea","family":"Giachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-6857","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Bitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-7184","authenticated-orcid":false,"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102640_bib1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102640_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0033-1354422","article-title":"Arthropathy in patients with moderate hemophilia a: a systematic review of the literature","volume":"39","author":"Di Minno","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102640_bib3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib6","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3324\/haematol.2019.242735","article-title":"Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies","volume":"105","author":"Peyvandi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102640_bib7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/jth.13491","article-title":"Advances in the treatment of bleeding disorders","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJMe2024545","article-title":"Treatment of hemophilia - more amazing progress","volume":"383","author":"Mannucci","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102640_bib13","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"Agosti","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102640_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102640_bib16","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.17225\/jhp00178","article-title":"Personalising haemophilia management with shared decision making","volume":"8","author":"Valentino","year":"2021","journal-title":"J\u00a0Haem Pract"},{"key":"10.1016\/j.rpth.2024.102640_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hum.2015.136","article-title":"Recombinant adeno-associated virus vector genomes take the form of long-lived, transcriptionally competent episomes in human muscle","volume":"27","author":"Schnepp","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2024.102640_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.rpth.2024.102640_bib22","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib23","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib24","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/mt.2012.197","article-title":"Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity","volume":"20","author":"Rosas","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpth.2024.102640_bib27","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102640_bib30","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib31","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.ymthe.2022.08.001","article-title":"AAV and hepatitis: cause or coincidence?","volume":"30","author":"de Jong","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib32","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2024.102640_bib34","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib39","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib41","first-page":"129","article-title":"SPK-8016: preliminary results from a phase 1\/2 clinical trial of gene therapy for hemophilia A","volume":"136","author":"Sullivan","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib42","first-page":"18","article-title":"Results from a phase 1\/2 safety and dose escalation study of TAK-754, an AAV8 vector with a codon-optimized B-domain-deleted factor VIII transgene in severe hemophilia A [abstract]","volume":"27","author":"Chapin","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib43","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2019-125764","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib44","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1566523222666220914105729","article-title":"Characteristics of BAY 2599023 in the current treatment landscape of hemophilia A gene therapy","volume":"23","author":"Pipe","year":"2023","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymthe.2017.12.007","article-title":"Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy","volume":"26","author":"VandenDriessche","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib47","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1182\/blood-2022-166135","volume":"140","author":"Pipe","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib49","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102640_bib50","first-page":"34","article-title":"Stable and durable factor IX levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B [abstract]","volume":"30","author":"von Drygalski","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib51","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","volume":"138","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100452","article-title":"OC 52.3 Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial [abstract]","volume":"7","author":"Cuker","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib53","first-page":"17","article-title":"A\u00a0novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe hemophilia B (HB) patients (B-AMAZE Study) [abstract]","volume":"4","author":"Chowdary","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib56","first-page":"3331","article-title":"101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102640_bib57","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102640_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102640_bib60","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102640_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.rpth.2024.102640_bib62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.rpth.2024.102640_bib63","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib64","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib65","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102640_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2024.102640_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.14545","article-title":"Gene therapy: practical aspects of implementation","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib69","first-page":"99","article-title":"Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B [abstract]","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtha.2022.11.026","article-title":"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists","volume":"21","author":"Miesbach","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib71","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2024.102640_bib72","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","article-title":"Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists","volume":"80","author":"M\u00fccke","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2024.102640_bib73","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102640_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2019.11.007","article-title":"Prednisolone does not regulate factor VIII expression in mice receiving AAV5-hFVIII-SQ: valoctocogene roxaparvovec","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rpth.2024.102640_bib75","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib76","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/clinchem\/46.12.2050","article-title":"Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2024.102640_bib77","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1182\/bloodadvances.2024013750","article-title":"Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice","volume":"8","author":"La Mura","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102640_bib78","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.jtha.2024.07.029","article-title":"Gene therapy for people with hemophilia B: a proposed care delivery model in Italy","volume":"22","author":"Castaman","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib79","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jtha.2024.08.018","article-title":"The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia","volume":"22","author":"La Mura","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib80","first-page":"93","article-title":"Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B [abstract]","volume":"5","author":"Schmidt","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.rpth.2024.102640_bib82","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","article-title":"Hemophilia gene therapy: approaching the first licensed product","volume":"5","author":"Batty","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.rpth.2024.102640_bib83","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpth.2024.102640_bib84","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nbt1007-1111","article-title":"AAV vectors and tumorigenicity","volume":"25","author":"Kay","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.rpth.2024.102640_bib85","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib86","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102640_bib87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.11.014","article-title":"Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists","volume":"78","author":"Miesbach","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2024.102640_bib88","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/hae.14887","article-title":"Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy","volume":"29","author":"Boban","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib89","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/hae.14440","article-title":"Implications of haemophilia gene therapy for the changing role of the multidisciplinary team","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib90","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in haemophilia treatment centres in the United States: practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib91","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/PPA.S355627","article-title":"The hemophilia gene therapy patient journey: questions and answers for shared decision-making","volume":"16","author":"Wang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2024.102640_bib92","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41434-022-00318-5","article-title":"Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy","volume":"30","author":"Fonck","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2003-37938","article-title":"Blood-induced joint damage in hemophilia","volume":"29","author":"Roosendaal","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102640_bib94","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH12-11-0874","article-title":"Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)","volume":"109","author":"Martinoli","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib95","article-title":"Ultrasound detection of subquadricipital recess distension","volume":"17","author":"Colussi","year":"2023","journal-title":"Intell Syst Appl"},{"key":"10.1016\/j.rpth.2024.102640_bib96","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/hae.12622","article-title":"Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A","volume":"21","author":"Aznar","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib97","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jum.16084","article-title":"Teleguidance for patient self-imaging of hemophilic joints using mobile ultrasound devices: a pilot study","volume":"42","author":"Aguero","year":"2023","journal-title":"J\u00a0Ultrasound Med"},{"key":"10.1016\/j.rpth.2024.102640_bib98","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtha.2022.12.027","article-title":"The ethics of gene therapy for hemophilia: a narrative review","volume":"21","author":"Baas","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102640_bib99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2516.2003.00725.x","article-title":"Gene therapy ethics and haemophilia: an inevitable therapeutic future?","volume":"9","author":"Dimichele","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01567.x","article-title":"Staunch protections: the ethics of haemophilia gene transfer research","volume":"14","author":"Kimmelman","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bmj.330.7482.79","article-title":"Recent developments in gene transfer: risk and ethics","volume":"330","author":"Kimmelman","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102640_bib102","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/sj.mt.6300316","article-title":"Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials","volume":"15","author":"Kimmelman","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2024.102640_bib103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2516.2004.00999.x","article-title":"What is a cure and how do we get there?","volume":"10","author":"Skinner","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib104","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","article-title":"The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study","volume":"17","author":"Fletcher","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2024.102640_bib105","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/hae.14822","article-title":"Development of a haemophilia A gene therapy shared decision-making tool for clinicians","volume":"29","author":"Limjoco","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102640_bib106","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","article-title":"Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia","volume":"37","author":"Thornburg","year":"2023","journal-title":"BioDrugs"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:14:57Z","timestamp":1762629297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924003352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2475037924003352"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102640","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy in hemophilia: the dawn of a new era","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102640"}}